# **Special Issue**

# Personalized Medicine and Multidisciplinary Approach in Biliopancreatic Endoscopy

## Message from the Guest Editor

Biliopancreatic endoscopy has undergone important changes and expansion over the last two decades. Not only are technologies around ERCP expanding, but also the different subtypes of procedures and indications are becoming more widespread, and subsequently, the number of professionals performing these techniques and coming from different specialties is increasing. The aim of this issue is to provide a comprehensive overview of all available multidisciplinary techniques that are involved in the treatment of biliopancreatic diseases. The advent of excellent imaging, better visualization. and excellent software makes the approach to biliopancreatic diseases by definition multidisciplinary. Team collaboration is essential for this highly dynamic environment. High definition cholangioscopy, 3D imaging of the biliopancreatic system, radiofrequency ablation, and endomicroscopy are some of the cuttingedge procedures that will be approached. Original research articles, cutting-edge procedures, literature reviews, and metanalyses are welcome.

### **Guest Editor**

Dr. Ivo Boškoski

- 1. Digestive Endoscopy Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Roma, Italy
- 2. Centre for Endoscopic Research Therapeutics and Training (CERTT), Università Cattolica del Sacro Cuore, 00168 Roma, Italy

### Deadline for manuscript submissions

closed (5 November 2020)



# Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed



### mdpi.com/si/38264

Journal of Personalized Medicine MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

jpm





# Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0 CiteScore 4.1 Indexed in PubMed



## About the Journal

## Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

### **Editor-in-Chief**

### Prof. Dr. David Alan Rizzieri

- 1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
- 2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

### **Author Benefits**

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC. Embase, and other databases.

### Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).

